Publication Name	World Journal of Gastroenterology
Manuscript ID	3681
Country	China

Received	2013-05-14 09:58
Peer-Review Started	2013-05-14 15:54
To Make the First Decision	2013-06-09 10:15
Return for Revision	2013-06-18 13:09
Revised	2013-07-02 11:06
Second Decision	2013-07-18 17:51
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-07-19 02:18
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-14 20:02
Publish the Manuscript Online	2013-08-27 16:46

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro
Manuscript Source	Invited Manuscript
All Author List	Feng-Rui Yang, Bu-Wu Fang and Jian-Shi Lou
Funding Agency and Grant Number	Funding Agency Grant Number Major Project of Applied Basic Research Plan of the Scientific and Technological Department of Tianjin, China 06YFJZJC 02900
Corresponding Author	Jian-Shi Lou, Professor, Department of Pharmacology, Tianjin Medical University, No. 22, Qixiangtai Road, Heping District, Tianjin 300070, China. jianshilou@126.com
Key Words	Fufang Biejia Ruangan Pill; Hepatic fibrosis; Transforming growth factor-Smad signaling
Core Tip	Fufang Biejia Ruangan Pill (FFBJRGP) is the first anti-fibrosis drug approved by the China State Food and Drug Administration. It has been demonstrated that FFBJRGP has a better efficacy of anti-fibrosis. However, the underlying therapeutic mechanisms of FFBJRGP in hepatic fibrosis are still unclear. In our study, FFBJRGP showed a strong ameliorative effect in hepatic fibrosis in vivo and in vitro. It reduced production and deposition of collagen in liver tissues. FFBJRGP inhibited expression of transforming growth factor (TGF-β1) and Smad3, which implied that inhibition of TGF-β/Smad-mediated fibrogenesis may be a central mechanism by which FFBJRGP protects against liver injury.
Publish Date	2013-08-27 16:46
Citation	Yang FR, Fang BW, Lou JS. Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro. World J Gastroenterol 2013; 19(32): 5326-5333
URL	http://www.wjgnet.com/1007-9327/full/v19/i32/5326.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i32.5326

Full Article (PDF)	WJG-19-5326.pdf
Manuscript File	3681-Review.doc
Answering Reviewers	3681-Answering reviewers.pdf
Copyright License Agreement	3681-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	3681-Language certificate.pdf
Peer-review Report	3681-Peer reviews.pdf
Scientific Editor Work List	3681-Scientific editor work list.doc